Retlirafusp plus chemo vs. standard anti-PD-1 plus chemo for advanced stomach cancer that has spread to the liver
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug combination (retlirafusp alfa plus chemotherapy) against a standard immunotherapy (PD-1 inhibitor) plus chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has spread to the liver and who haven't had prior treatment for advanced disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced stomach or gastroesophageal junction cancer that has spread to the liver (confirmed by biopsy).
- You have not had any prior chemotherapy or immunotherapy for advanced cancer. (Previous treatment after surgery is okay if it ended more than 6 months ago.)
- You are in fairly good physical condition (able to do light activities, not bedridden).
- You have at least one tumor that can be measured on scans.
- You agree to use effective birth control (if you or your partner could become pregnant) during the study and for 120 days after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (SHR-1701) combined with chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal metastasis) but not to other organs like the liver or lungs. The goal is to see if this combination can help shrink or control the cancer before any surgery.
This trial tests a new immunotherapy drug (Retlirafusp Alfa) combined with chemotherapy before surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor enough to allow surgery, and is for patients with specific types of HER2-negative or low-HER2 cancer and a PD-L1 CPS score of 1 or higher.
This trial tests a new drug called retlirafusp alfa combined with chemotherapy as a treatment before and after surgery for a specific type of stomach cancer. It aims to see if this combination is safe and effective for patients whose cancer has a high level of a certain protein (CPS > 5) and is not driven by HER2.
This trial tests a combination of three drugs to treat stomach or junction cancer that has spread or come back after initial immunotherapy treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two targeted drugs (adebrelimab and fruquintinib) plus chemotherapy (paclitaxel or albumin-bound paclitaxel) for people with advanced gastric or gastroesophageal junction cancer whose disease progressed after prior PD-1 antibody treatment. The goal is to see if this new combination can help when standard options have stopped working.
This trial tests a new drug called retlirafusp alfa combined with standard chemoradiotherapy for people with esophageal cancer that cannot be surgically removed. The goal is to see if this combination is safe and effective in shrinking tumors and improving outcomes.
Hear when a new Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.